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ABSTRACT 
 
Objective: The Bristol Impact of Hypermobility (BIoH) questionnaire is a patient-reported outcome 
measure developed in conjunction with adults with Joint Hypermobility Syndrome (JHS). It has 
demonstrated strong concurrent validity with the Short Form-36 (SF-36) physical component score 
but other psychometric properties have yet to be established. This study aimed to determine its test-
retest reliability and smallest detectable change (SDC). 
Design: A test-retest reliability study. 
Setting: Participants were recruited from the Hypermobility Syndromes Association, a patient 
organisation in the United Kingdom. 
Patients: Recruitment packs were sent to 1,080 adults who had given permission to be contacted 
about research. 
Main Outcome Measures: BIoH and SF-36 questionnaires were administered at baseline and 
repeated two weeks later. An 11-point global rating of change scale (-5 to +5) was also administered 
at two weeks. Test-retest analysis and calculation of the SDC was conducted on ‘stable’ patients 
(defined as global rating of change -1 to +1). 
Results: 462 responses were received. 233 patients reported a ‘stable’ condition and were included 
in analysis (95% women; mean (SD) age 44.5 (13.9) years; BIoH score 223.6 (54.0)). The BIoH 
questionnaire demonstrated excellent test-retest reliability (ICC 0.923, 95% CI 0.900-0.940). The SDC 
was 42 points (equivalent to 19% of the mean baseline score). The SF-36 physical and mental 
component scores demonstrated poorer test-retest reliability and larger SDCs (as a proportion of the 
mean baseline scores). 
Conclusion: The results provide further evidence of the potential of the BIoH questionnaire to 
underpin research and clinical practice for people with JHS. 
 
 
  
MANUSCRIPT 
 
INTRODUCTION 
Joint Hypermobility Syndrome (JHS) is a heritable connective tissue disorder characterised by 
excessive joint range of motion and pain (Grahame, 2003). It was previously widely recognised that 
there was a lack of distinction in the clinical presentation of JHS and Ehlers-Danlos Syndrome, 
Hypermobility Type (EDS-HT) (Tinkle et al., 2009) and many authors considered them to be the same 
condition. Indeed recent revision of the classification of EDS has created a more specific diagnostic 
category to replace both of those terms, this being ‘hypermobile EDS’ (hEDS) (Malfait et al., 2017). 
Where patients have symptomatic joint hypermobility but do not meet the diagnostic criteria for other 
syndromes, the term ‘Hypermobility Spectrum Disorder’ (HSD) has been adopted (Castori et al., 
2017). As the research described in this paper pre-dated the new criteria the term JHS will be used. 
 
There is a distinct lack of good epidemiological data on the prevalence of JHS, although it is likely to 
be high in musculoskeletal services. For example 30% of a convenience sample of 150 patients 
screened in a musculoskeletal triage service in the United Kingdom (UK) (Connelly et al., 2015) met 
the Brighton diagnostic criteria (Grahame et al., 2000). It should be acknowledged, however, that JHS 
may not have been the reason for referral and it is unlikely that many of these patients would have 
ordinarily received a diagnosis of JHS. The condition is associated with a wide range of problems 
including pain, fatigue, reduced proprioception and repeated cycles of injury (Terry et al., 2015). The 
psychological impact of JHS is also well recognised, including agoraphobia, anxiety, 
catastrophisation, depression, fear and panic disorders (Terry et al., 2015; Smith et al., 2014a). 
 
Physiotherapy, particularly exercise, is a mainstay of treatment for JHS (Hakim and Grahame, 2004; 
Keer and Grahame, 2003; Simmonds and Keer, 2007; Simmonds and Keer, 2008; Tinkle, 2008; Keer 
and Simmonds, 2011). The research evidence for the effectiveness of therapy is inconclusive 
however, with a limited number of low quality studies reported in the literature (Palmer et al., 2014; 
Smith et al., 2014b). A recent pilot randomised controlled trial (RCT) of a complex physiotherapy 
intervention demonstrated positive effects on a range of clinical outcomes (Palmer et al., 2016), 
although such effects have yet to be confirmed in an adequately powered clinical trial. 
 A survey of physiotherapy practice in the UK (Palmer et al., 2015) suggested that there was a 
mismatch between what physiotherapists considered to be the aims of physiotherapy for JHS and the 
outcome measures that they used to assess the effectiveness of management. A condition-specific 
outcome measure has therefore recently been developed in close collaboration with adults with JHS 
in an attempt to more adequately capture the wide-ranging impact of the condition (Palmer et al., 
2017).  The ‘Bristol Impact of Hypermobility’ (BIoH) questionnaire gives a maximum score of 360, with 
higher scores representing more severe impact of the condition on the person’s life. It has strong 
concurrent validity (r=-0.725, n=615) with the physical component score of an established general 
health questionnaire, the Short Form-36 (SF-36) (Palmer et al., 2017). The SF-36 was chosen as a 
comparator as it has previously been demonstrated to be sensitive to change following an exercise 
intervention (Ferrell et al., 2004). Although the BIoH questionnaire has demonstrated initial promise, it 
needs further evaluation before it can be used confidently to support future research and clinical 
practice in this area. Adequate test-retest reliability is an important psychometric property for an 
outcome measure, ensuring that scores are constant over time in those patients who report that their 
condition is stable (Polit, 2014). 
 
This project therefore aimed to conduct a test-retest reliability evaluation of the BIoH questionnaire 
over a two-week period and to calculate the smallest detectable change (SDC). Secondary aims were 
to conduct a limits of agreement analysis and an exploratory sensitivity to change analysis. Findings 
were compared with the SF-36. 
 
 
METHODS 
This study received a favourable opinion from the Faculty of Health & Applied Sciences Ethics Sub-
Committee, University of the West of England, Bristol, UK (HAS/15/01/99). 
 
Recruitment 
Recruitment packs were distributed to 1,080 adult members of the Hypermobility Syndromes 
Association (HMSA) who had given permission to be contacted about research. The HMSA is a 
patient organisation in the UK. Packs included a letter of invitation, information sheet, consent form, a 
brief demographic and screening questionnaire, and copies of the BIoH and SF-36v2 (OptumInsight 
Life Sciences Inc.) questionnaires. The information sheet included an invitation to contact the 
research team for additional information if required. Those willing to take part were asked to complete 
and return the consent form and questionnaires using a pre-paid envelope. Completion of the BIoH 
questionnaire takes approximately 10 minutes (Palmer et al., 2017) and the SF-36 7-10 minutes 
(Coons et al., 2000). The inclusion criteria were: ≥16 years old; fulfilled two or more JHS screening 
questions (Hakim and Grahame, 2003) and/or received a formal diagnosis (by a healthcare 
professional) of JHS or EDS-HT; no other formally diagnosed conditions affecting physical function; 
written informed consent; complete baseline and follow-up BIoH questionnaire data. The JHS 
screening questionnaire has previously demonstrated 84% sensitivity and 80-89% specificity (Hakim 
and Grahame, 2003). 
 
Two weeks later repeat BIoH and SF-36 questionnaires were sent to consenting participants to 
complete independently, along with a global rating of change (GRC) scale (Kamper et al., 2009). A 
retest period of one to two weeks is typical for many test-retest studies (Polit, 2014). To allow 
sufficient time for postal administration of the questionnaires and because the BIoH asks about the 
previous seven days, a period of two weeks was chosen. The GRC scale was an 11-point numerical 
rating scale which asked patients "With respect to your joint hypermobility, how would you describe 
yourself now compared with two weeks ago when you last completed this questionnaire (please circle 
a number)?" Anchors were at -5 ("Very much worse"), 0 ("Unchanged") and +5 ("Very much better"). 
 
No formal sample size calculation was conducted, although a minimum of 50 participants is 
recommended for limits of agreement analysis (Altman, 1991; Terwee et al., 2007). It was anticipated 
that many more participants would be recruited as a 42% response rate from HMSA members was 
previously achieved when initially developing the BIoH questionnaire (Palmer et al., 2017). 
 
Data analysis 
Data analysis was conducted using IBM SPSS Statistics (IBM Corp. Released 2015. IBM SPSS 
Statistics for Windows, Version 23.0. Armonk, NY: IBM Corp). The BIoH questionnaire scoring 
guidelines were followed to calculate BIoH scores (Palmer et al., 2017). SF-36 scoring software 
(Version 4.5. Lincoln, RI: OptumInsight Life Sciences Inc.) was used to calculate SF-36v2 component 
scores. Questionnaire data was manually entered into an SPSS spreadsheet (SM, PhD) and the 
accuracy of data entry was audited and verified by a second researcher (SP, PhD).  
 
The same analysis procedures were used for the BIoH and SF-36 questionnaires. Test-retest 
reliability analysis was conducted on ‘stable’ patients (defined as those who scored -1 to +1 on the 
GRC score). This was to ensure that assessment of test-retest reliability was not contaminated by 
fluctuations in patients’ conditions, a common feature of JHS (Terry et al., 2015). A change of plus or 
minus one point on an 11-point GRC scale is considered to be clinically unimportant (Kamper et al., 
2009). Descriptive statistics were used to compare the characteristics of ‘stable’ patients against the 
wider sample of patients who met the inclusion criteria. Intraclass Correlation Coefficient (ICC) (two-
way mixed effects, single measure, absolute agreement) (Koo and Li, 2016), standard error of 
measurement (SEM) for agreement and SDC were calculated for the BIoH questionnaire and SF-36 
scores (Polit, 2014). Details for calculation of the SEM and SDC are available in Table 3.  The 95% 
limits of agreement were plotted for the BIoH scores (Bland and Altman, 1986).  
 
An exploratory sensitivity to change analysis was conducted in all participants who met the inclusion 
criteria. A scatterplot explored the relationship between GRC score and change in BIoH score. 
Pearson’s correlation coefficients further explored the relationships between GRC scores and change 
in BIoH and SF-36 scores.  
 
 
RESULTS 
462 responses were received from HMSA members (43% response rate). 99 were excluded on the 
following basis: 82 failed to return week two questionnaires; Seven had incomplete follow-up data; 
Five had been diagnosed with another connective tissue disease; Three were <16 years; One could 
not be diagnosed with JHS on the basis of the screening questions; One had incomplete baseline 
data. A total of 363 participants therefore met the inclusion criteria and completed baseline and follow-
up BIoH questionnaires. Of these, 233 scored between -1 and +1 on the GRC score across the two-
week study period and thus were classified as ‘stable’ for the purposes of the test-retest reliability 
analysis. Kolmogorov-Smirnov tests confirmed that data for the BIoH questionnaire and SF-36 PCS 
conformed to a normal distribution at both baseline and two-weeks (n=233). Although the SF-36 MCS 
data deviated from normality (n=233), a pragmatic decision was made to use parametric analysis 
throughout as the choice of statistical approach for analysis of SF-36 data in people with chronic pain 
has previously been found to have no effect on the outcome (Torrance et al 2009). 
 
Table 1 illustrates that there were no systematic differences between ‘stable’ participants (n=233) and 
the larger sample of participants who met the inclusion criteria (n=363), suggesting that the ‘stable’ 
patients were representative of the larger group from which they came. Table 2 presents information 
relating to the diagnostic make-up of the wider sample (n=363). 
 
The distribution of GRC scores across the full data set (n=363) can be seen in Figure 1. ‘No change’ 
was defined as a GRC score from -1 to +1 (n=233). An ICC value of 0.923 (95% Confidence Interval 
(CI) 0.900-0.940) was calculated for the BIoH questionnaire, indicating excellent test-retest reliability 
(n=233). Corresponding values for the SF-36 Physical Component Score (PCS) and Mental 
Component Score (MCS) were ICC 0.887 (95% CI 0.855-0.912) and ICC 0.778 (95% CI 0.721-0.825) 
respectively (n=233). 
 
Calculations relevant to limits of agreement analysis are contained in Table 3. The mean difference in 
BIoH scores across the two weeks for ‘stable’ patients (n=233) was -3.26 points, suggesting a trend 
towards slightly lower scores on repeat testing. The 95% CI for ?̅? for the BIoH questionnaire did not 
cross zero which confirms slight bias on repeated measurement (in this case a tendency towards a 
lower score at week two) (Rankin and Stokes, 1998). The SDC (1.96 SD of the difference scores) for 
the BIoH questionnaire was calculated to be 42 points (equivalent to 12% of the maximum score 
(360 points) or 19% of the mean baseline score (223.6 points) observed in the current sample) 
(n=233). The corresponding values for the SF-36 PCS and MCS were 9 and 15 points respectively 
(equivalent to 9% and 15% of the maximum score (100 points) or 25% and 37% of the mean baseline 
scores (33.6 and 41.8 points) respectively) (n=233).  
 
The 95% limits of agreement were calculated as the mean difference ± the SDC. Figure 2 presents 
the limits of agreement plot for the BIoH questionnaire (Bland and Altman, 1986) (n=233). It is difficult 
to identify clear trends but there is perhaps slightly greater between-days differences (the difference in 
score between baseline and week 2) in the region of the mean BIoH scores (the mean baseline score 
was 223.6). These differences seem to be smaller at either end of the range of between-days mean 
scores, particularly in the lower range. 
 
The relationship between the GRC score and change in the BIoH questionnaire score across the two-
week study period is illustrated in Figure 3 for all participants who met the inclusion criteria (n=363). 
This demonstrates a moderate negative correlation (Pearson’s correlation coefficient r=-0.493, 
p<0.001), indicating that improvement measured by the GRC scale was associated with a decrease in 
the impact of the condition as measured by the BIoH questionnaire. Corresponding SF-36 values 
were r=0.186 (p<0.001) and r=0.203 (p<0.001) for the PCS and MCS respectively, indicating weak 
associations between GRC and improvement in disability as measured by the SF-36. 
 
 
DISCUSSION 
The BIoH questionnaire has demonstrated excellent test-retest reliability over a two-week period, with 
an ICC value of 0.923. Test-retest reliability coefficient values in excess of 0.85 have previously been 
recognised as indicating ‘excellent’ reliability (Polit, 2014). In the present investigation even the lower 
boundary of the ICC 95% confidence interval for the BIoH questionnaire was equal to 0.9 so this 
indicates that the questionnaire performed very strongly in this regard. The PCS of the SF-36 also 
performed very well with an ‘excellent’ ICC value of 0.887. The MCS performed less well, with an ICC 
value of 0.778, although this would still be classified as ‘adequate’ by many researchers (Polit, 2014). 
So, both the BIoH questionnaire and SF-36 PCS demonstrated excellent test-retest reliability in the 
context of this study, with marginally better reliability for the BIoH questionnaire. 
 
The SDC values suggested that a change of 42 points or more on the BIoH questionnaire might be 
considered beyond measurement error (equivalent to 19% of the mean score observed in the current 
sample). A change of less than this is therefore unlikely to be important clinically. The corresponding 
SDC values for the SF-36 PCS and MCS were equivalent to 25% and 37% of the mean scores 
respectively. This suggests that the BIoH questionnaire may be more sensitive to change, at least in 
terms of the relative magnitude of measurement error. However it should be acknowledged that these 
estimates are only based on the boundaries of error around the change score in ‘stable’ patients 
(Wright et al., 2012). The minimum clinically important difference would therefore need to be verified 
through analysis of sensitivity of change following interventions of known efficacy. 
 
A further preliminary analysis of sensitivity to change was performed by analysing the relationship 
between GRC scale scores and change in the BIoH questionnaire and SF-36 values across the two-
week study period. This suggested that the BIoH performed much better, with correlation values 
approaching -0.5 compared to values for the PCS and MCS in the region of 0.2. This supports an 
assumption that the BIoH questionnaire may be more sensitive, although again this needs to be a 
very tentative interpretation until a more robust evaluation of sensitivity to change is conducted. 
 
A number of different outcome measures have been used in previous JHS clinical trials. For example 
the patient-reported outcome measures used in previous trials of exercise for adults with JHS 
included in a recent systematic review (Palmer et al., 2014) were the SF-36 (Ferrell et al., 2004), the 
Arthritis Impact Measurement Scales 2 (AIMS-2) (Sahin et al., 2008) and a questionnaire developed 
by Barton and Bird (1996). Of those, only the SF-36 captured improvements following exercise 
(Ferrell et al., 2004). Only one of the five AIMS-2 subscales improved (Sahin et al., 2008), and no 
changes were evident in the questionnaire used by Barton and Bird (1996). The SF-36 questionnaire 
was thus a good candidate against which to compare the BIoH questionnaire (Palmer et al., 2017). A 
fuller critical evaluation of these studies is available in the systematic review by Palmer et al (2014). 
 
The prevalence of pain was shown to be very high, with participants reporting pain in a mean of 8 out 
of 10 body areas, a similar prevalence to that previously observed (Palmer et al., 2017). This is 
perhaps unsurprising as participants in both studies were recruited from the same patient 
organisation. Nonetheless, it reinforces the observation that the pain experienced by those with JHS 
is widespread.  
 
Additional information related to the five-point screening questionnaire of Hakim and Grahame (2003) 
has been gathered, suggesting that some questions might be more discriminative than others (Table 
2). For example shoulder or kneecap dislocation was only reported by 38% of respondents. The 
original developers of the questionnaire found similarly low proportions for positive responses to that 
question, with only 20% and 38% of their cohorts giving an affirmative answer (Hakim and Grahame, 
2003). The questionnaire now forms a supplementary part of the diagnostic criteria for hEDS in cases 
where the Beighton criteria is one point below the age-related cut-off (Malfait et al., 2017). As such, 
further evaluation of the psychometric properties of the five-point questionnaire is warranted and 
could include an evaluation of sensitivity and specificity against the primary diagnostic criteria. 
Although many experts have historically considered JHS and EDS-HT to be the same condition 
(Tinkle et al., 2009) it was interesting to note that the diagnostic label of JHS (92%) was more 
commonly reported by participants in this study than EDS-HT (63%). It is not known how many 
participants would meet the new diagnostic criteria for hEDS (Malfait et al., 2017). 
 
Strengths and limitations 
The sample included in the present investigation was very similar to that included in initial validation of 
the BIoH questionnaire (Palmer et al., 2017). This is perhaps not surprising as participants were 
recruited through the same patient organisation. The sample was slightly more ethnically diverse than 
that previously recruited by Palmer et al (2017), although it could still not be considered 
representative. For example 87.1% of the UK population described themselves as ‘white’ in the 2011 
census (Office for National Statistics, 2013), as opposed to 95.3% of all eligible participants or 93.5% 
of ‘stable’ participants in the present investigation. The sample also lacked diversity in terms of sex 
(95% women) and educational attainment was much higher than might be expected (25% reported 
having a postgraduate degree). Although there is generally a lack of good epidemiological data in this 
area, Engelbert et al (2004) suggested that the prevalence of symptomatic joint hypermobility in 
adults might be 3.3% of women and 0.6% of men. This gives a woman: man ratio of approximately 
5.5 : 1, as opposed to the much higher 19 : 1 of respondents in the present investigation. This might 
limit the generalisability of study findings. 
 
Use of the five-point JHS screening questionnaire (Hakim and Grahame, 2003) was a strength of the 
study design. A limitation of the methodology used in the initial validation of the BIoH questionnaire 
was that a diagnosis of JHS was self-declared (Palmer et al., 2017). Whilst the present investigation 
still relied upon self-report in relation to the screening questions, the questionnaire has previously 
exhibited high sensitivity and specificity for JHS (Hakim and Grahame, 2003). This increases 
confidence in relation to the diagnostic status of participants, although it cannot be assured for all 
individuals as sensitivity and specificity are 16% and 11-20% short of perfection respectively. 
 
Conclusion 
The present investigation demonstrated that the BIoH questionnaire performed better than the SF-36 
PCS and MCS in terms of test-retest reliability. The BIoH questionnaire SDC was also smaller than 
either SF-36 subscale (as a proportion of the mean baseline scores). In addition, there was a stronger 
correlation between change in the BIoH score and the GRC score than either the SF-36 PCS or MCS, 
suggesting that it may be more sensitive to change. However, as already suggested, analysis of 
sensitivity to change following interventions of known efficacy would be necessary to confirm such 
speculation. It is clear that, on the basis of the psychometric properties investigated in the present 
study, the BIoH questionnaire performed very well when compared against the SF-36. The results 
provide further evidence of the psychometric properties of the BIoH questionnaire, enhancing 
confidence in its potential use for clinical research and practice. 
 
 
HIGHLIGHTS 
• The BIoH questionnaire demonstrated excellent test-retest reliability. 
• The smallest detectable change was calculated to be 42 points. 
• The BIoH questionnaire performed better than the SF-36. 
• Confidence in using the BIoH questionnaire for research and practice is enhanced. 
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Participant characteristics and baseline outcome 
scores 
All participants  
(n=363) 
‘Stable’ 
participants 
(n=233) 
Age, mean  SD (years) 43.8  13.7 44.5  13.9 
Sex, women : men (% women) 346 : 17 (95.3%) 221 : 12 (94.8%) 
Relationship status, n (%) Single 100 (27.6%) 71 (30.5%) 
Marrried/ partner 223 (61.6%) 134 (57.5%) 
Divorced/ separated 30 (8.3%) 21 (9.0%) 
Widowed 7 (1.9%) 5 (2.1%) 
Other 2 (0.6%) 2 (0.9%) 
Living arrangements, n 
(%) 
Alone 61 (16.9%) 45 (19.4%) 
With husband/ wife/ partner 222 (61.5%) 132 (56.9%) 
With somebody else 78 (21.6%) 55 (23.7%) 
Education Years at school, mean  
SD (years) 
12.8  1.5 12.8  1.5 
College diploma or 
equivalent, n (%) 
Yes 203 (67.2%) 
No 99 (32.8%) 
Yes 135 (67.8%) 
No 64 (32.2%) 
A university degree or 
equivalent, n (%) 
Yes 175 (56.3%) 
No 136 (43.7%) 
Yes 114 (57.9%) 
No 83 (42.1%) 
A postgraduate degree 
(e.g. PhD), n (%) 
Yes 67 (25.0%) 
No 201 (75.0%) 
Yes 43 (25.1%) 
No 128 (74.9%) 
Paid job at present, n (%) Yes 195 (54.5%) 127 (55.2%) 
No 163 (45.5%) 103 (44.8%) 
Nature of paid job, n (%) Part-time 88 (48.1%) 59 (50.9%) 
Full-time 95 (51.9%) 57 (49.1%) 
Self-employed 30 (18.9%) 21 (20.4%) 
Employee 129 (81.1%) 82 (79.6%) 
No paid job at present, n 
(%) * 
Retired 45 (26.2%) 32 (28.1%) 
Unemployed and seeking 
work 
15 (8.7%) 11 (9.6%) 
Early retired due to 
sickness or disability 
79 (45.9%) 50 (43.9%) 
Full time student 13 (7.6%) 7 (6.1%) 
Doing voluntary work 22 (12.8%) 15 (13.2%) 
At home doing housework 29 (16.9%)  22 (19.3%) 
Ethnicity, n (%) White 344 (95.3%) 216 (93.5%) 
Mixed 6 (1.7%) 6 (2.6%) 
Asian 2 (0.6%) 2 (0.9%) 
Black 2 (0.6%) 2 (0.9%) 
Chinese 1 (0.3%) 1 (0.4%) 
Other  6 (1.7%) 4 (1.7%) 
Baseline BIoH score, mean  SD 228.8  53.8 223.6  54.0 
Baseline BIoH score, range 42-326 42-325 
Baseline number of body pain areas, mean  SD 8.0  2.1 7.8  2.1 
Baseline SF-36 PCS 32.8  8.9 33.6  9.2 
Baseline SF-36 MCS 41.7  11.6 41.9  11.6 
Table 1. Characteristics and baseline outcome scores for all participants (n=363) and the 
subgroup of ‘stable’ participants (GRC score -1 to +1, n=233). % figures are expressed as a 
proportion of valid responses to each question. *Responders could choose more than one option so 
total % may be more than 100% (% is expressed as a proportion of those responding to this question, 
n=172 and n=114 respectively). MCS = mental component score; PCS = physical component score; 
SD = standard deviation; SF-36 = Short Form-36 questionnaire. 
 
  
Criteria for diagnosis ‘Yes’ n  
(%) 
A. Hakim and Grahame 
(2003) criteria 
≥2/5 of the criteria below 338/363  
(93.1%) 
1. Can you now (or could you ever) place your hands 
flat on the floor without bending your knees? 
312/361  
(86.4%) 
2. Can you now (or could you ever) bend your thumb 
to touch your forearm? 
280/363  
(77.1%) 
3. As a child did you amuse your friends by contorting 
your body into strange shapes OR could you do the 
splits? 
262/360  
(72.8%) 
4. As a child or teenager did your shoulder or 
kneecap dislocate on more than one occasion? 
137/361  
(38.0%) 
5. Do you consider yourself double-jointed? 249/359  
(69.4%) 
B. Have you received a 
formal diagnosis (from a 
healthcare professional) 
of: 
≥1 of the criteria below 351/363 
(96.7%) 
1. Joint Hypermobility Syndrome 286/310  
(92.3%) 
2. Ehlers Danlos Syndrome – Hypermobility Type 
(formerly EDS-III) 
189/302  
(62.6%) 
Met criteria A. and/or B. 363/363 
(100%) 
Table 2. Criteria used to confirm a diagnosis of JHS for all participants (n=363). % figures are 
expressed as a proportion of valid responses to each question.  
Outcome measure ?̅?  
(95% CI) 
SDdiff SEM SDC 95% LoA 
BIoH  
(max 360 points), n=233 
-3.26  
(-5.98, -0.54) 
21.20 14.99 41.55 -44.81, 38.29 
SF-36 PCS  
(max 100 points), n=227 
0.00  
(-0.57, 0.57) 
4.37 3.09 8.56 -8.56, 8.57 
SF-36 MCS  
(max 100 points), n=227 
0.55  
(-0.48, 1.58) 
7.88 5.57 15.44 -14.89, 16.00 
Table 3. Calculations related to limits of agreement analysis. BIoH = Bristol Impact of 
Hypermobility questionnaire; CI = confidence interval; ?̅? = mean difference scores; LoA = Limits of 
agreement; MCS = mental component score; PCS = physical component score; SDC = Smallest 
Detectable Change (calculated as 1.96 x SDdiff); SDdiff = standard deviation of difference scores (the 
difference in score between baseline and week 2); SEM = standard error of measurement (calculated 
as SDdiff  2); SF-36 = Short Form-36 questionnaire. 
  
  
Figure 1. Distribution of global rating of change scores for all participants (n=363).  
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Figure 2. BIoH questionnaire limits of agreement plot for ‘stable’ participants (GRC score -1 to 
+1, n=233). Mean between days BIoH scores are plotted against the between days difference in BIoH 
scores for each individual participant. The superimposed lines depict the mean difference score (solid 
line) and 95% limits of agreement (dashed lines). LoA = Limit of Agreement. Mean diff = mean 
difference. 
  
-80
-60
-40
-20
0
20
40
60
80
0 50 100 150 200 250 300 350
B
et
w
ee
n
 d
ay
s 
d
if
fe
re
n
ce
 in
 B
Io
H
 
q
u
es
ti
o
n
n
ai
re
 s
co
re
s
Between days mean BIoH questionnaire score
Upper LoA = 38.29
Lower LoA = -44.81
Mean diff = -3.26
 Figure 3. Scatterplot of global assessment of change score against change in BIoH 
questionnaire score for all participants (n=363). 
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